• Product name
    Human PML+RARA Fusion peptide


  • Nature
  • Amino Acid Sequence
    • Species

Associated products


Our Abpromise guarantee covers the use of ab46898 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Form
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • MYL
    • NR1B1
    • Nuclear receptor subfamily 1 group B member 1
    • Nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form
    • PP8675
    • Promyelocytic leukemia
    • Promyelocytic leukemia protein
    • Promyelocytic leukemia, inducer of
    • RAR
    • RAR-alpha
    • RARA alpha
    • RARAalpha1
    • Retinoic acid receptor alpha polypeptide
    • Retinoic acid receptor, alpha
    • RING finger protein 71
    • RNF71
    • TRIM19
    • Tripartite motif protein TRIM19
    • Tripartite motif-containing protein 19
    see all
  • Relevance
    PML protein is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This phosphoprotein localizes to nuclear bodies where it functions as a transcription factor and tumor suppressor. Its expression is cell-cycle related and it regulates the p53 response to oncogenic signals. Retinoic acid, a metabolite of vitamin A, is necessary for normal organogenesis but acts as a teratogen at high levels during embryonic and fetal development. Retinoic acid functions through its interaction with the nuclear protein, retinoic acid receptor (RAR). RAR belongs to the steroid and thyroid hormone superfamily of nuclear receptor proteins which exert their effects by binding to specific DNA response elements, thus regulating gene expression in target cells. RAR exists as three major subtypes: alpha, beta and gamma.
  • Cellular localization
    Nuclear and Cytoplasmic


ab46898 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A


Thank you for contacting us.

As discussed previously, the PML RARa Fusion peptide is a 10 amino acid residue peptide taken from with the region 500-600 of the PML+RARa Fusion protein. This peptide is ideally suited to being used in blocking peptide studies with the anti-PML+RARA Fusion antibody (ab43152) for which it was used as the immunogen.

This peptide (ab46898) comprises the region across the PML-RAR alpha junction in the L-type fusion protein. The peptide has not been rearranged in any way.

I hope this information has been of help. If you have any further questions, please do not hesitate to ask.

Read More


Thank you for contacting us.

I am please to say that we have this peptide in stock currently so if the customer places an order soon it can be sent out with your next delivery.

I hope this information has been of help. If you require any further information please do not hesitate to contact us again.

Read More


Thank you for contacting us.

Unfortunately the sequence information is considered proprietary. I can however say that the peptide sequence is taken from within the residues 500-600 of the human PML+RARa Fusion. This peptide comprises the region across the PML-RAR alpha junction in the L-type fusion protein.

I am sorry that I could not be of more assistance in this instance. If you have any further questions please do not hesitate to ask.

Read More


Sign up